AURA vs CSTL
AURA: Aura Biosciences is a clinical-stage biotech developing targeted, light-activated virus-like drug conjugates (VDCs) designed to treat ocular cancers while preserving organ function and vision. CSTL: Castle Biosciences is a molecular diagnostics company offering gene expression profile tests to improve management of dermatologic and gastrointestinal cancers.
Side-by-side fundamentals
| Metric | AURA | CSTL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $6.51 | $33.71 | |
| Market cap | $675M | $1.0B | |
| Net margin FY2025, SEC XBRL | n/a | -7.0% | |
| Operating margin FY2025, SEC XBRL | n/a | -12.4% | |
| ROE FY2025, SEC XBRL | -77.6% | -5.1% | CSTL higher |
| ROA FY2025, SEC XBRL | -62.7% | -4.2% | CSTL higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.02 | AURA lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +3.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.94 | 0.82 | |
| 1-year return as of 2026-10-08 close | +6.8% | +42.9% | CSTL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.